BAYER AG

Company Snapshot

Founded: 1863
Entity Type: Public
Employees: 92,815
Region: Europe/Africa/Middle East and Asia/Pacific
Revenue: $50,437.5 Millions
Revenue Year: 2024
Segment: Pharmaceuticals
Headquarter: Leverkusen, Germany
Key Geographics: North America, Europe, Africa, Middle East, Asia-Pacific, Latin America
Corporate Address: 51368 Leverkusen, Germany Tel: +49-214-301 Web: www.bayer.com

Company Overview

Bayer AG is a life science company with core competencies in healthcare and agriculture. It manages its business through three divisions: pharmaceuticals, consumer health, and crop science.

Bayer’s pharmaceutical division focuses on prescription products (name few Kogenate, Betaseron. Cipro (Ciprofloxacin), Adempas (Riociguat), and Xofigo (Radium-223 dichloride) ), especially cardiology; women’s health; and specialty therapeutics in oncology, hematology and ophthalmology. Cell and gene therapy is one of the company’s focus areas. It has established an independent strategic unit for cell and gene therapy.

Consumer Health is a leading supplier of OTC medicines, nutritional supplements, medicated skincare products, and other self-care solutions for pain, cardiovascular risk prevention, dermatology, digestive health, allergy, and cough and cold.

BAYER AG In Reports

Therapies for Rheumatoid Arthritis: Technologies and Global Markets

BCC Research expert says the Therapies for Rheumatoid Arthritis market report analyzes the market trends of therapies for rheumatoid arthritis with data from 2024, estimates from 2025, projections of CAGR through 2030. ...

Global Irritable Bowel Syndrome and Inflammatory Bowel Disease Therapeutics Market

BCC Research Market Analyst says global market for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) therapeutics is expected to grow from $33.3 billion in 2025.

Global Markets for Allergy Diagnostics and Treatments

BCC Research Market Analyst says global market for allergy diagnostics and treatment is projected to grow from $67.8 billion in 2025 to $96.4 billion by the end of 2030.

Company's Business Segments

  • Crop Science : Crop protection, seeds and traits, digital farming, fruits & vegetables, environmental science.
  • Pharmaceuticals : Treatments and therapies, Cell and gene therapies.
  • Consumer Health : Nutritional supplements, Allergy, Cough & cold, Dermatology, Pain and cardiovascular risk prevention, Digestive health.
  • All other segmements
  • Enabling Functions and Consolidation

Applications/End User Industries

  • Cardiology
  • Hematology
  • Oncology
  • Chronic Kidney Disease
  • Eye Condition
  • Healthy Aging
  • Hormonal and Reprodcutive Health
  • Digital Farming System
  • Seeds
  • Traits
  • Crop Protection
  • Climate Change
  • Environmental Science
  • Personal Health
AI: Your Say